NDA 22-527
GILENYA® ( fingolimod ) 0.5mg capsules
Sphingosine 1-phosphate Receptor Modulator

Novartis Pharmaceuticals Corporation
One Health Plaza
East Hanover, NJ 07936

RISK EVALUATION AND MITIGATION STRATEGY (REMS)
1 Goals

The goal of the GILENYA® (fingolimod) REMS is:

- To inform healthcare professionals (HCPs) about the serious risks of GILENYA (fingolimod) including bradyarrhythmia and atrioventricular (AV) block at treatment initiation, infections, macular edema, posterior reversible encephalopathy syndrome (PRES), respiratory effects, liver injury, and fetal risk.

2 REMS Elements

2.1 Communication Plan

Novartis will implement a communication plan to HCPs to support implementation of the REMS. The communication plan includes the:

1. Dear Healthcare Professional Letter (DHCPL)

   This letter for prescribers includes information about the approved indication for GILENYA and describes the contraindications for use, the potential serious risks of the product, including bradyarrhythmia and AV block following initiation of treatment, infections, macular edema, posterior reversible encephalopathy syndrome, respiratory effects, liver injury, and fetal risk. It also summarizes the specific recommendations and monitoring related to these risks, based on relevant sections of the revised Package Insert (PI) dated May 2015. The letter also includes information about the GILENYA Pregnancy Registry and encourages prescribers to register patients.

   The communication plan will target the following HCPs:

   Potential prescribers of GILENYA: The main prescribers of GILENYA are neurologists with experience in treating patients with MS. A list of potential prescribers will be compiled from IMS data providing prescribers of MS drugs and the membership list from the Consortium of Multiple Sclerosis Centers.

2. Dear Professional Society Letter

   A letter will be provided to the leadership of the following professional societies: Consortium of Multiple Sclerosis Centers, the American Academy of Neurology, the American Neurology Association, and the National Multiple Sclerosis Society. The content of the letter will be the same as described above for the DHCPL, with the exception of the introduction and a statement describing that the leadership of the society should distribute the letter to their members.

3. Guide to Important Safety Information: Using GILENYA in Patients with Relapsing Forms of Multiple Sclerosis
This guide will present more detail on the safety information related to bradyarrhythmia and AV block following initiation of treatment, infections, macular edema, posterior reversible encephalopathy syndrome, respiratory effects, liver injury, and fetal risk. It also highlights contraindications for GILENYA, information about each risk and guidance for prescribers related to monitoring and counseling of patients at treatment initiation and during GILENYA therapy. The guide also includes information about the GILENYA Pregnancy Registry and encourages prescribers to register patients.

4. GILENYA REMS website

The GILENYA REMS website (www.gilenyarems.com) will contain the current full Prescribing Information (PI), the DHCPL, the Dear Professional Society Letter, the Guide to Important Safety Information: Using GILENYA in Patients with Relapsing Forms of Multiple Sclerosis, and information about the GILENYA Pregnancy Registry. The GILENYA REMS website will be available until September 21, 2015.

Distribution of the DHCPL, Dear Professional Society Letter and the Guide to Important Safety Information will be sent by direct mail via the US Postal Service regular mail according to the following timeline.

a) Letters were sent within 60 days of approval of the REMS, on September 21, 2011, and June 26, 2013.

b) Letters must be sent within 30 days of this REMS modification approval.

c) Novartis will ensure that all materials listed in or appended to the GILENYA REMS will be available through the GILENYA REMS website. This information will be available on the website until September 21, 2015. All of these materials will also be available by request through Novartis’s toll-free information number (1-888-NOW-NOVA or 1-888-669-6682), through Novartis sales representatives and field-based medical personnel.

The following materials are part of the REMS and are appended:

(i) DHCPL
(ii) Dear Professional Society Letter
(iii) Guide to Important Safety Information: Using GILENYA in Patients with Relapsing Forms of Multiple Sclerosis
(iv) GILENYA REMS website

3 Timetable for Submission of Assessments

REMS assessments will be submitted to the FDA at 18 months, 3 years, 4 years, and 7 years from the initial date of approval of the REMS (September 21, 2010). An additional assessment is also required to be submitted 11 months from the date of approval of the May 2015 REMS Modification Supplement. To facilitate inclusion of as much information as possible while allowing reasonable time to prepare the submission, the reporting interval covered by each
assessment should conclude no earlier than 60 days before the submission date for each assessment time interval. Novartis will submit each assessment so that it will be received by the FDA on or before the due date.